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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a systemic disease; morbidity and mortality due to
COPD are on the increase, and it has great impact on patients' lives. Most COPD patients are managed by general
practitioners (GP). Too often, GPs base their initial assessment of patient's disease severity mainly on lung function.
However, lung function correlates poorly with COPD-specific health-related quality of life and exacerbation frequency.
A validated COPD disease risk index that better represents the clinical manifestations of COPD and is feasible in primary
care seems to be useful. The objective of this study is to develop and validate a practical COPD disease risk index that
predicts the clinical course of COPD in primary care patients with GOLD stages 2–4.
Methods/Design: We will conduct 2 linked prospective cohort studies with COPD patients from GPs in Switzerland
and the Netherlands. We will perform a baseline assessment including detailed patient history, questionnaires, lung
function, history of exacerbations, measurement of exercise capacity and blood sampling. During the follow-up of at least
2 years, we will update the patients' profile by registering exacerbations, health-related quality of life and any changes in
the use of medication. The primary outcome will be health-related quality of life. Secondary outcomes will be
exacerbation frequency and mortality. Using multivariable regression analysis, we will identify the best combination of
variables predicting these outcomes over one and two years and, depending on funding, even more years.
Discussion: Despite the diversity of clinical manifestations and available treatments, assessment and management today
do not reflect the multifaceted character of the disease. This is in contrast to preventive cardiology where, nowadays,
the treatment in primary care is based on patient-specific and fairly refined cardiovascular risk profile corresponding to
differences in prognosis. After completion of this study, we will have a practical COPD-disease risk index that predicts
the clinical course of COPD in primary care patients with GOLD stages 2–4. In a second step we will incorporate
evidence-based treatment effects into this model, such that the instrument may guide physicians in selecting treatment
based on the individual patients' prognosis.
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Background
The majority of Chronic Obstructive Pulmonary Disease
(COPD) patients are treated in primary care [1]. COPD is
a leading cause of morbidity and mortality worldwide
with an increasing prevalence, especially in women and
an increasing economic and social burden. Management
of COPD is challenging because of the diversity of clinical
manifestations and available treatments [2]. General prac-
titioners (GP) need to select those treatments that will
improve the individual patient's health status and clinical
course (prognosis) most. However, recent surveys on
COPD management show that a majority of physicians
do not consider the patient's severity of disease when pre-
scribing COPD treatments and that current medical prac-
tice deviates substantially from the GOLD guidelines [3-
6]. For example, most patients receive inhaled steroids
although only patients with frequent exacerbations and/
or Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stage 3 and 4 may benefit [7-9]. Conversely, pul-
monary rehabilitation and long-term oxygen are pre-
scribed rarely for patients with advanced COPD despite
strong evidence supporting their effectiveness [3,4,10,11].
These results suggest that GPs may not have methods
available to sufficiently consider severity of disease and
projected prognosis given particular treatment decisions.
Assessment of disease severity should not focus solely on
lung function because it correlates, at best, moderately
with clinically relevant outcomes such as health-related
quality of life, dyspnea, or exacerbations. An increasing
body of evidence shows that additional information
should be ascertained that better reflects disease severity
[12-15]. And indeed, in their latest guidelines, the Euro-
pean Respiratory Society and American Thoracic Society
state that "it is accepted that a single measurement of
Forced Expiratory Volume in one second (FEV1) incom-
pletely represents the complex clinical consequences of
COPD" and that additional parameters should be ascer-
tained [2].
There is one index, the BODE index, that follows this line
by incorporating FEV1, dyspnea, body mass index and
exercise capacity (6-minute walking test) into a single
index [14]. It provides information about COPD patients'
prognosis and may help tailoring therapy to a particular
patient's risk. However, although the BODE index (B =
Body Mass Index, O = Obstruction, D = Dyspnea and E =
Exercise capacity) represents a substantial advance in
COPD evaluation, it has important limitations hindering
its application in primary care. First, the 6-minute walking
test is currently not easily applicable outside a rehabilita-
tion setting. Second, the development process of the
BODE index was not optimal; potentially important
information about disease severity such as history of exac-
erbations, current smoking or arterial oxygen pressure was
not considered in the development process. Third, the
BODE index predicts mortality, which hardly guides phy-
sicians in selecting treatments. Fourth, the BODE index
was developed in COPD clinics and it has not been vali-
dated in any clinical or primary care population. Often,
risk indices perform worse in other populations or set-
tings, which could lead to inadequate predictions fol-
lowed by suboptimal decisions affecting patient
management and possibly outcome [16]. These limita-
tions currently make the BODE index unsuitable for pri-
mary care settings. A recent survey illustrates this: only
28% of GPs said they had heard about the BODE index
and 0% knew any of its components [5].
Therefore, a disease risk index for COPD patients should
be developed using more advanced methods and one that
is applicable in primary care. The European Respiratory
Society and American Thoracic Society also call for a mul-
tivariable disease risk tool; "a staging system that could
offer a composite picture of disease severity is highly desir-
able, although it is currently unavailable" [2]. This is also
in line with the growing interest in the medical commu-
nity for risk-stratification based on multivariable evalua-
tion.
Respiratory medicine might gain from emulating the
approach taken in preventive cardiology. Cardiovascular
risk can be estimated based on several parameters, as
shown in Figure 1, which in turn guide selection of treat-
ments (so-called risk index-guided treatment). Corre-
spondingly, future COPD management might look as
shown in Figure 2. Assessment by a risk index would
inform the optimal selection of COPD treatments target-
ing current symptoms and limitations as well as slowing
down disease progression. Thus, COPD management
would be individualized and, thereby, on average, tai-
lored better to a particular patient's needs.
In conclusion, the aim of the ICECOLD ERIC study is to
develop and validate a practical COPD disease risk index
that predicts the clinical course of COPD in primary care
settings. In this study, we will identify important risk pre-
dictors for health-related quality of life, exacerbation risk
and mortality. In a second step we will try to incorporate
treatment effects into the model using data from the study
itself and (external) data from pertinent RCTs and meta-
analyses. This instrument will guide treatment on the
individual patient's COPD severity.
Methods/Design
Study design
We will conduct two prospective cohort studies (Swiss
and Dutch counterparts), following a similar study proto-
col. We hope to be able to collect data from other cohort
studies with similar protocols at a later stage. Figure 3 con-BMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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tains a flow chart of the study. The study has been
approved of by all local ethic committees and is registered
on the website http://www.ClinicalTrials.gov with the
identifier: NCT00706602.
Outcomes
The primary outcome, for which the risk index will be
developed, will be COPD-specific health-related quality
of life as measured by the Chronic Respiratory Question-
naire (CRQ). COPD-specific health-related quality of life
is one of the main outcomes used in prognostic COPD
research whether observational or interventional [11-13].
Secondary outcomes will include COPD exacerbations
requiring medical treatment and mortality.
Population
We will include patients ≥ 40 years of age with COPD in
GOLD stage 2–4 (postbronchodilator FEV1/FVC ≤ 0.70
and postbronchodilator FEV1 ≤ 80% of predicted), who
are able to complete the baseline assessment and who
have been free of exacerbation for at least four weeks.
Exclusion criteria will be a life expectancy of ≤ 12 months
(predicted by the patient's GP), dementia, psychosis or
other psychiatric morbidity that invalidates assessment of
patient-reported parameters such as health-related quality
of life, physical activity or dyspnea, and inability to com-
plete the baseline assessment due to language difficulties.
These criteria will be evaluated in cooperation with the
participating GPs by browsing the patients' charts and
during the eligibility testing.
Recruitment of GPs and patients
In Switzerland, we will invite GPs from private practice in
the cantons of Zurich and St. Gallen using a two-stage
strategy. In a first step, we will involve GPs from the
North-Eastern part of Switzerland whom we know to have
an active interest in research activities. Through these GPs
we will identify more GPs potentially willing to partici-
pate (snowballing approach). In a second step, we will
invite the latter to participate. We will send them a bro-
chure describing the background and aim of the study as
well as what participation entails. Also, we will outline the
benefits of participation. Participating GPs will identify
potentially eligible patients through electronic or paper-
based patient charts. For electronic patient charts, GPs will
search with the key terms "copd", "chronic bronchitis",
"emphysema", "asthma" and a combination of "smok-
ing", "≥ 40 years of age" and "male" to identify patients
with obstructive airway disease. Paper-based patient
charts will be screened by hand. The participating GPs
inform potentially eligible patients about the purpose of
the study, the involvement of university investigators and
the eligibility testing procedure. Patients indicating a wish
to participate will be invited by telephone for eligibility
testing. After obtaining a first informed consent, investiga-
tors will perform the eligibility testing and, if proven eligi-
ble, obtain a second informed consent to participate in
the study before proceeding to the baseline assessment.
In the Netherlands, we will include COPD patients from
GPs registered in the GP research network of the Depart-
ment of General Practice, University of Amsterdam (HAG-
net Academic Medical Centre) and Zorggroep Almere. The
HAG-net Academic Medical Centre consists of 7 health
care centres, ± 45 GPs and ± 45,000 patients. The Zorg-
groep Almere consists of 22 health care centres, ± 120 GPs
and ± 165,000 patients. GPs will identify potentially eligi-
ble patients through the electronic patient charts and will
send them study information and an invitation letter. We
will use the 'opt-out method', meaning that patients who
are not interested to participate or who do not permit us to
telephone them have to return a reply card indicating so.
By telephone, study personnel invites for eligibility testing
all patients who did not respond via the reply card within
10 days. After obtaining informed consent to participate
in the study, investigators will perform the eligibility test-
ing and, if proven eligible, proceed to the baseline assess-
ment.
Eligibility testing
The study personnel will assess whether the patients have
COPD stage II–IV using portable and hand-held spirome-
try (EasyOne Model 2001 diagnostic spirometer, ndd
Cardiovascular (CV) risk assessment and treatment choice Figure 1
Cardiovascular (CV) risk assessment and treatment 
choice; based on several parameters, patients fall into a spe-
cific colored box (details are illegible) and the color corre-
sponds to a risk profile (green = low risk, orange = medium 
risk and red = high risk). According to that risk profile, treat-
ment recommendation(s) are given.
Assessment
Smoking history
Blood pressure
cholesterol
Age and sex
Lifestyle advice and 
reassessment
Low risk (0-5%) Medium risk (5-10%) High risk (>10%)
Lifestyle advice +/-
drug treatment
Lifestyle advice + 
drug treatmentBMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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Medizinaltechnik, Zürich, Switzerland). This spirometer
uses ultrasonic flow measurements and determines sev-
eral lung function parameters. For our purpose, we will
determine postbronchodilator FEV1 and Forced Vital
Capacity (FVC) as a measure for airflow obstruction and
the Inspiratory Reserve Volume (IRV) as a measure for
hyperinflation. Ten minutes before measuring lung func-
tion, patients will inhale two puffs of 100 μg salbutamol
through a spacer. Informing the patient about the study,
obtaining informed consent and lung function testing will
require about 30 minutes.
Baseline assessment
Baseline assessment is standardized and includes history
taking, completion of self-administered questionnaires,
testing of exercise capacity and blood sampling. To ensure
comparability across centres and countries, we have devel-
oped and pilot tested case report forms and instructions
for testing. Investigators will meet at least twice a year to
ensure that the baseline assessment remains identical in
both countries. The baseline assessment takes about 60
minutes to complete.
The following data will be ascertained at baseline by study
personnel:
Patient history
￿ General information: date of birth, sex, living situa-
tion, (former) occupation and education.
￿ COPD-specific: study personnel will enquire after
the year the diagnosis of COPD was made, smoking
history, current smoking and smoking exposure at
home. The number of pack years (1 pack year = smok-
ing 20 cigarettes per day for one year) will be calcu-
lated. We will rely on patient-reported smoking.
Ideally, smoking is determined chemically using car-
boxyhemoglobin (CO-Hb). Although CO-Hb will be
measured in this study, it is likely that GPs using the
risk index in the future will determine current smoking
by interview instead of measuring CO-Hb.
￿ Exacerbations: since ascertainment of exacerbations
is challenging [17,18], we will use several approaches
to identify them. First, study personnel will ask the
patients how many exacerbations they have had in the
previous year. Second, this will be checked in the elec-
tronic or hand-written patient charts for documented
in- and outpatient treatments. To be counted as an
exacerbation, 2 criteria must be fulfilled;
1. unscheduled physician contact in a hospital, pri-
vate practice or by telephone for worsening of dys-
pnea, cough, increased sputum production and/or
a change in sputum color
2. electronic or hand-written documentation of a
new prescription or a dosage increase of systemic
steroids and/or new prescription of an antibiotic.
￿ Dyspnea scale: we will use the Medical Research
Council (MRC) dyspnea scale [19]. The MRC scale
ranges from 0 (not troubled by breathlessness except
on strenuous exercise) to 4 (too breathless to leave the
house or breathless when (un)dressing).
￿ Chronic cough and phlegm: we will use the ques-
tions about cough and phlegm from the Swiss Cohort
Study on Air Pollution and Lung Diseases in Adults
(SAPALDIA) Questionnaire [20]. In Switzerland, the
original version in German will be used; in the Neth-
erlands a Dutch version will be used. Two translators
independently translated the German version of the
SAPALDIA questionnaire into Dutch. After consensus,
another translator, unaware of the original German
version, backtranslated this Dutch version of the
SAPALDIA questionnaire and the backtranslated ver-
sion appeared to be similar to the original German
version.
￿ Comorbidities: by asking the patient and screening
the patient chart, study personnel will register whether
the patient has been diagnosed with cardiovascular
disease, cerebrovascular disease, diabetes, current or
previous cancer, musculoskeletal disease or other
chronic disease. Study personnel will also register the
current health status, e.g. current infections.
￿ Drugs: study personnel will register the prescribed
drugs at that moment as documented in the patient
chart, including yearly influenza and pneumococcal
vaccination.
COPD exacerbation risk assessment and treatment choice  (example) Figure 2
COPD exacerbation risk assessment and treatment 
choice (example); based on several parameters, patients 
fall into a specific risk profile (green = low risk, orange = 
medium risk and red = high risk). According to that risk pro-
file, treatment advice(s) are given.
Smoking history
Lung function  Assessment
- smoking cessat
-
ion
bronchodilatators
Low risk Medium risk High risk
- smoking cessation
- bronchodilatators
- patient education
- training
Previous exacerbations
Physical activity
For a decline in 
COPD-specific  
health-related  
quality of life
smoking cessation -
bronchodilatators -
- patient education
training -
inhaled steroids -BMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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flow chart Figure 3
flow chart.
Assessment of eligibility: 
-lung function 
-assessment of in- and 
exclusion criteria 
Identification of potential 
patients by GP 
Information about study and 
informed consent 
Baseline assessment (T=0): 
If not eligible, stop  If eligible, proceed to 
baseline assessment 
-patient history 
-questionnaires 
-exercise capacity tests 
-blood sample 
Follow-up 1, 2, 3 
(T= 6, 12, 18 months): 
-patient history 
-questionnaires 
Follow-up 4 (T=24 months): 
-patient history 
-questionnaires 
-lung function 
-exercise capacity tests BMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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￿ Other therapies: study personnel will register if the
patients have had long-term oxygen therapy, physical
training, lung surgery, lung revalidation etc.
￿ Body Mass Index: study personnel will measure
weight and height to derive the Body Mass Index
(BMI).
Questionnaires
￿ COPD-specific health-related quality of life: we will
use the widely used and validated Chronic Respiratory
Questionnaire (CRQ) in a Dutch and German version
[21,22]. The 20 questions of the CRQ provide sum-
mary scores for four domains that are deemed impor-
tant to COPD patients (dyspnea, fatigue, emotional
function, and mastery). Patients answer each question
on a seven-point scale to express the degree of disabil-
ity from 1 (maximum impairment) to 7 (no impair-
ment). The total score and score per domain can be
calculated by using the mean value ranging from 1 to
7. We will use the self-administered version that takes
5–10 minutes to complete. A change of 0.5 in CRQ
domain scores represents the minimal important dif-
ference [23].
￿ Feeling thermometer: the Feeling thermometer is a
validated visual analogue scale presented as a ther-
mometer with 100 marked intervals [24-26]. The
worst (dead = 0) and the best (perfect health = 100)
health states are defined anchors and facilitate com-
parisons between individuals and groups. We will ask
patients to reflect in their score how they have felt in
the last seven days.
￿ Self-efficacy instrument: self-efficacy is the patient's
belief in his or her skills to manage the illness. It is
associated with medication compliance and might be
a prognostic factor. We will use a short COPD-specific
instrument to measure the patient's self-efficacy. It
contains 3 questions about the management of their
illness on a five-point scale from 1 (not confident) to
5 (very confident).
￿ Anxiety and depression: for affective disorders, com-
mon in COPD patients and contributing to health-
related quality of life, we will use the Hospital Anxiety
and Depression Scale (HADS) [27]. The HADS has
been developed and validated to assess symptoms of
anxiety and depression in patients with physical
impairment. There are seven items for each domain
(anxiety and depression) with statements on emotions
and emotional situations. Patients express their agree-
ment with the statements on a scale from 0 to 3.
Domain scores are calculated by summing up the
scores for the seven items resulting in scores from 0
(no depression/anxiety) to 21 (depression/anxiety
very likely to be present). Scores ≥ 8 indicate that there
is an increased probability of an affective disorder
being present. A change of 1.5 in HADS domain scores
represents the minimal important difference [23,28].
We will use the self-administered version that takes
around 5 minutes to complete.
￿ Self-reported activity: we will use the Physical Activ-
ity Questionnaire (LAPAQ) from the Longitudinal
Ageing Study Amsterdam (LASA) [29]. The LAPAQ is a
validated questionnaire available in English and
Dutch that covers the frequency and duration of walk-
ing outside, bicycling, gardening, household activities
and sport activities during the previous two weeks. The
questionnaire takes 5–10 minutes to complete. Since
there was no German version available we have devel-
oped one. Three translators independently translated
the Dutch LAPAQ into German. After a consensus
meeting a first version of the LAPAQ was generated
that was considered to be identical to the Dutch ver-
sion. We then pilot tested the German LAPAQ for its
comprehensibility in COPD patients. Another transla-
tor unaware of the original Dutch version backtrans-
lated the LAPAQ and the backtranslated version was
compared with the original LAPAQ in order to exclude
conceptual differences. A formal validation process of
the German LAPAQ is currently ongoing.
There is one difference between the Dutch and Ger-
man LAPAQ. In the Netherlands walking and bicy-
cling for transportation purposes are considered as
common daily activities and not as sports activities.
This is not the case in Switzerland where bicycling is
mostly a sports activity. Therefore, we decided to add
a question to the German version containing the fre-
quency and duration of walking uphill because walk-
ing uphill is a daily activity for many people in
Switzerland. We made this addition in collaboration
with the developers of the original LAPAQ.
To counteract potential order effects that might result if
patients are, for example, tired after one questionnaire or
more tired completing the LAPAQ than completing the
CRQ, we will randomize the order of questionnaire
administration. Patients are assigned one out of six differ-
ent orders. We will use a computerized block randomiza-
tion to generate the randomization list.
Exercise Capacity
We will use 2 tests to measure the exercise capacity.
￿ Sit-to-stand test: this test is performed using a chair
without arm rests. The test is first demonstrated by
study personnel. Patients are requested to hold their
hands on their hips and to complete the sitting and
standing positions as correctly and as fully as possibleBMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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without using the arms for support. After a cue,
patients stand upright and without delay sit down
again, repeating the procedure as many times as possi-
ble in a 1 minute period at a self-selected speed in
which they feel safe and comfortable (taking rests at
their own discretion). Care is taken to be in full exten-
sion motion and approximately 90 grade flexion
motion in knee joint. The number of completed repe-
titions is recorded. The patients are permitted to have
rest periods to complete 1 minute [30].
￿ Handgrip test: we will use the Hand Dynamometer
(JA Preston Corp, Ontario, Canada) to assess grip
strength of both hands. The measurements are per-
formed while the patients are seated with the shoul-
ders adducted, elbows flexed to 90° and forearms in
the neutral position. The test will be performed three
times in each hand.
Blood sample
Five tubes (two heparin tubes, one serum tube and two
EDTA tubes) of venous blood will be taken to test for
parameters with potential associations with COPD-spe-
cific health-related quality of life decline, exacerbations,
death and for future testing of blood markers and genetic
factors in order to protect our study from early out-of-dat-
edness. Although genetic testing is not routine yet in
COPD, there are a number of polymorphisms with poten-
tial prognostic significance. We comply closely with the
guidelines for biobanks of the Swiss Academy of Medical
Sciences [31]. To ensure correct sampling, storage and
genetic analysis, the samples will be coded. The decoding
is stored at the Horten Centre in Zurich, Switzerland, and
the Academic Medical Centre in Amsterdam, the Nether-
lands, and is only accessible to the investigators. The
blood samples will be taken to the laboratories in Zurich
and Amsterdam by the study personnel. One heparin tube
will be used for determining carboxyhemoglobin and the
second for testing blood markers (C-reactive protein, total
cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol, triglycerides, creatinin,
bilirubin, alanine-aminotransferase, gamma-glutamyl-
transferase and glucose). The remaining blood and the
serum tube will be distributed to four aliquots and stored
at -80°C in freezers located at University Hospitals of
Zurich and Amsterdam. One EDTA tube will serve to
extract DNA and the second to count leucocytes and to
perform a differential blood count. The blood samples
will be stored for a maximum duration of 20 years.
Follow-up
Currently, funding is assured for at least two years of fol-
low-up. For an extension of the follow-up, additional
funding is required. We will contact patients half-yearly
by telephone to ascertain outcomes and to update the
patients' profile using the baseline patient history form
and we will send them the questionnaires. After two years
we will additionally measure lung function and exercise
capacity again. We will ask patients about exacerbations
during the follow-up interviews. In addition, the Swiss
GPs will be asked to complete a form each time an exacer-
bation occurs and fax it to the study center. The Dutch
investigators will review the patient charts for possible
exacerbations. Thus, this combination of means to docu-
ment exacerbations will minimize the chance of missing
exacerbations requiring medical treatment, Also, for each
patient, an independent and blinded adjudication com-
mittee (2 experienced pulmonologists and 1 GP) will
check all clinical evidence from all available documents to
judge whether the doctor or hospital visits were due to an
exacerbation and to distinguish these from other events
mimicking exacerbations such as heart failure.
To take into account changes in the patients' profile over
time, we will interview patients during follow-up about
dyspnea, cough, physical activity, smoking status and
treatment as described above. Based on experience in ear-
lier studies, these follow-up interviews will require about
25 minutes.
Statistical analysis – prediction model
In choosing an approach to the statistical analysis, the use
of the risk index in practice should be kept firmly in mind.
The goal is prediction of the course of illness as expressed
in health-related quality of life, risk of exacerbation and
mortality. In principle, the CRQ has four domains (dysp-
nea, fatigue, emotional function, and mastery) and
domain-specific predictions probably will trigger different
therapeutic actions. So, potentially, seven different predic-
tion models can be built: 4 on the CRQ domains, one for
the overall CRQ score, one for exacerbation risk, and one
for mortality, respectively. These models are likely to have
at least some predictors in common. We envision that a
practitioner will collect all predictors and receive a pattern
of 7 predictions to discuss with the patient and base the
therapy on. The added value of information whose collec-
tion requires more time (sit-to-stand test, questionnaires)
will be systematically assessed. Obviously, the different
endpoints require the use of different regression tech-
niques: linear regression (CRQ), Cox regression for recur-
rent events (exacerbations) and Cox or logistic regression
for mortality.
In clinical terms we envision the use of a prediction model
in the following situations. First, in patients who visit the
practice and are first diagnosed as having COPD. And sec-
ond, in patients known to have COPD, who are identified
through the electronic patient charts for a scheduled fol-
low up visit. Our model will not be optimally suitable for
use at unscheduled visits, triggered perhaps by exacerba-
tions due to our exclusion criterion on current exacerba-
tions.BMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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Issues important in constructing multivariable models
depend on the purpose of the multivariable model (cor-
recting for confounding in studying causal effects, explor-
atory analyses that try to identify independent risk factors,
or prediction models). Even with the purpose in mind,
there seems to be consensus that there is no consensus on
how one should build multivariable models [32-34].
Here we will restrict to issues important in constructing
prediction models. In particular, the issue of variable
selection is contentious. Very often, subject matter knowl-
edge is not of much help, since that has already been
incorporated into the questionnaire development and the
measurement of other (e.g. blood-based) determinants.
Such questionnaires most often contain more items than
a realistic model may tolerate. We favor parsimonious
models because most clinicians have little time. Even data
reduction techniques such as principal component analy-
sis applied to many predictors, as proposed by Harrell
[33], although facilitating efficient model fitting, still
forces physicians to collect a lot of data. Usually there is
no time to do that, although (in the future) there may
increasingly be exceptions where part of the information
may be collected from electronic patient charts or in the
waiting room through an internet connection or from
home prior to the actual visit. Most experts think that uni-
variable screening of predictors should not be performed
and we will avoid that.
Missing values in limited amounts and if scattered
throughout different predictors may be dealt with by mul-
tiple imputation although it may require additional soft-
ware programming to perform for example bootstrapped
variable selection in more than one imputed data set and
elegantly integrate the results from each imputed data set
into a single model. By contrast, many missing data on
just one or a few tests may indicate that such data will end
up missing in practice too, so imputation and incorpora-
tion of such a test in a prediction rule seems unwise.
Royston and Sauerbrei emphasize the importance of
modeling continuous predictors correctly, avoiding
unnecessary categorization They argue that multivariable
fractional polynomials may be seen as a flexible and con-
venient compromise between ultra-flexible but poten-
tially unstable local influence models, such as
(smoothing) splines and relatively inflexible global influ-
ence models, such as for example conventional polynomi-
als [34]. We think that they argue their case convincingly
and will explore multivariable fractional polynomials for
our continuous predictor candidates such as age, exercise
capacity test results and blood values.
The biggest issue of contention seems to be the one of var-
iable selection. There is the choice between full models
(which, as stated above, we think are impractical due to
physicians' time restraints), backward elimination,
shrinkage, lasso (least absolute shrinkage and selection
operator) or least angle regression (LAR) and finally, one
we think has much potential, the garotte [34-36]. The
garotte is a shrinkage approach in which the degree of
shrinkage is reduced as the predictor's regression coeffi-
cient gets larger. This is attractive since, according to
Copas, large coefficients do not need (much) shrinkage.
Lasso and general shrinkage may shrink large coefficients
too much. A drawback of the garotte is that it starts with a
full model which may be too large to fit. We expect to be
able to explore the garotte if we succeed in programming
it. The final model may still be subjected to enhanced
bootstrap procedure to estimate over-optimism. This is
usually expressed as the difference between areas under
the curve or Brier scores. We will explore any over-opti-
mism in the predicted values and their corresponding
confidence intervals.
In much of the literature on prediction of cardiovascular
disease, ongoing treatments in observational cohorts are
not (explicitly) accounted for. This seems to be incorrect
because it is easy to envision that the prognosis of a
patient with high blood pressure while on antihyperten-
sive treatment differ from a patient with high blood pres-
sure without any treatment. For example in COPD, the
prognosis of a patient with a low MRC score while on
bronchodilators can differ from the prognosis of a patient
with the same MRC score without bronchodilators. In
ICECOLD ERIC we collect data on treatment (changes)
and intend to use them in the models where necessary.
We will have several options to validate our prediction
model. For example, the Dutch cohort could be the deri-
vation set and the Swiss cohort the validation set or vice
versa. One of other possibilities is that half of each cohort
could be used as derivation set and the other half as vali-
dation set. Or, we can even combine all data to derive the
model and test the model via bootstrap. At the time of
writing, we have not decided which route we will follow.
At the time we need to make that decision, we will try to
find the best solution at that moment according to the sta-
tistical literature.
Discrimination of the model(s) will be visualized in high
resolution histograms and summarized as 5th, 10th, 25th
50th, 75th, 90th, and 95th centiles of these, Brier score and
the area under the receiver operating characteristics curve
(ROC) with 95% confidence intervals (overall discrimina-
tion)[37]. Using the regression coefficients of the inde-
pendent diagnostic indicators, an easy to use,
multivariable diagnostic rule (clinical index) will be
derived, consisting of relevant tests and their diagnosticBMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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values [38]. Calibration will be assessed using Hosmer
Lemeshow tests and visualized using calibration plots
(observed versus expected (or rather, model-based) prob-
abilities).
Statistical analysis – selecting patient management
A prediction rule is not a decision rule [39]. For physi-
cians, it may be unclear how predictive information may
be employed to change a patient's management benefi-
cially. We would like to incorporate knowledge on treat-
ment effects into our model(s) to guide physicians and
patients in their decisions on how management should
change given the predicted probabilities that a predictive
model provides. In that respect, separate prediction of
long-term outcomes for the sub domains of the CRQ may
be much more unequivocal than a prediction of the total
score in one or two years time. So, it is still attractive to
explicitly model effects of treatment as to provide physi-
cian and patient with predictions conditional on particu-
lar treatments. Although the ICECOLD ERIC cohort(s)
contain some information on treatment effects, we expect
that the combined evidence from RCTs on COPD or good
meta-analyses thereof may be a more fruitful source to see
how predictions may be altered beneficially. This topic is
currently being debated by our group and we cannot be
more specific here.
Sample size
The number of covariables that we will consider for the
regression analysis is roughly 20, and using the rule that
at least ten times as many patients are needed than covari-
ables considered, we will need at least 200 patients per
population.
Data collection and quality control
We will implement a series of measures to ensure high
data quality.
1. Site investigators will collect the data using standard-
ized forms.
2. All data will be collected and entered into a single data-
base in MS-Access at the Academic Medical Centre pro-
vided by the Department of Clinical Epidemiology,
Biostatistics and Bio-informatics. All data will be double
entered and checked by a compare procedure.
3. International investigator meetings will be held (at
least) twice yearly for all staff involved in data collection
to detect any divergence in data collection procedures.
This involves site mutual visits whenever possible.
4. Local investigators meetings will be held monthly, or
more frequently if needed, to discuss recruitment of
patients and problems in conducting the study.
5. E-mail will serve as the first line of non-urgent commu-
nication between research team members.
6. In Switzerland, monthly reports will be prepared by the
principal investigator and sent to all GPs to inform about
the number of patients recruited and important issues
concerning the conduction of the study.
Discussion
Management of COPD is challenging due to the various
treatment options and the heterogeneous character of the
disease. The actual (as opposed to ideal) assessment and
treatment choices today are quite similar for all COPD
patients and are often based on too few disease character-
istics. This often leads to undertreatment of patients with
severe COPD and overtreatment of patients with mild
COPD. An example of overtreatment is the widely pre-
scribed inhaled corticosteroids in mild patients. Results
from recent studies suggest that GPs may not have meth-
ods available to sufficiently consider severity of disease for
treatment decisions [3-11].
In preventive cardiovascular care, treatment decisions are
based on the cardiovascular risk profile of the individual
patient in primary care. Based on the most important pre-
dictors, patients fall into a specific risk profile. These pro-
files are formally coupled with treatment effects and costs
considerations. Based on these components, treatment
recommendations may be made. We believe that this so
called risk index-guided treatment for specific patient pro-
files may well be applicable to COPD too.
The aim of this study to develop and validate a practical
COPD disease risk index for the primary care will individ-
ualise and improve COPD management. Assessment of
disease severity should not focus solely on lung function.
An increasing body of evidence shows that additional
information should be ascertained that better reflects dis-
ease severity than lung function [2,12-15].
We expect that after this study, the disease risk index will
be ready for use in primary care. It will divide COPD-
patients into specific risk profiles (low, medium and high
risk) for each of the outcomes; COPD-specific health-
related quality of life (domain-specific), exacerbation risk
and mortality. In a second step we will incorporate treat-
ment advices into the model by using data mainly from
pertinent RCTs and meta-analyses. Ways to incorporate
treatment advices into the prediction model may be chal-
lenging and are currently being explored by our team. In
the development process of the cardiovascular risk model,
the relative risk (RR) was treated as constant across all risk
profiles.
Thus a predicted risk of cardiovascular death within 10
years of 30% may be reduced by RR = 0.8 to 24% (abso-BMC Pulmonary Medicine 2009, 9:15 http://www.biomedcentral.com/1471-2466/9/15
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lute risk reduction = 6%) whereas the same RR reduces a
3% predicted risk to 2.4% (absolute risk reduction =
0.6%). Adding costs considerations may lead to a recom-
mendation to treat the former, and not the latter patient.
It is unclear whether in our study, examining COPD, we
will have the luxury of finding convincing evidence of
constancy of relative risks (or odds ratios) of different
treatments. If not, we will have to develop more refined
methods.
Using the risk score that we will develop, the management
of COPD in primary care will improve. Treatment deci-
sions will be tailored better to the needs of the individual
patient, resulting in less unnecessary treatment prescrip-
tions, less exacerbations and a better COPD-specific
health-related quality of life. We also expect that COPD
management will become more cost-effective.
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